Japan-based pharmaceutical manufacturer Delta-Fly Pharma Inc (TOKYO: 4598) announced on Wednesday that it has commenced patient enrollment for its Phase III clinical trial of DFP-14323 in combination with Afatinib (20 mg/day) versus Afatinib (40 mg/day) alone in stage III/IV non-small cell lung cancer (NSCLC) patients with uncommon EGFR mutations.
Approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in February 2024, this trial will be conducted at 30 sites in Japan.
The primary endpoint is to confirm the superiority of DFP-14323 in progression-free survival (PFS). DFP-14323 targets aminopeptidase N, which is highly expressed in lung cancer and inflammatory cells, potentially offering effective treatment for refractory cancer patients regardless of EGFR mutation types.
Plans are underway to expand the trial to other Asian countries with high numbers of EGFR mutation-positive NSCLC patients. Delta-Fly Pharma will also seek out-licensing opportunities with Asian pharmaceutical companies.
Johnson & Johnson agrees acquisition of V-Wave
Nightingale Health gains UKCA certification and expands with new laboratory
Talphera enrols first subject in NEPHRO CRRT study
China Pharma Holdings anticipates launch of Dry Eye Disease Therapeutic Device in early 2025
SOPHiA DDM Platform achieves IVDR certification, enhancing diagnostic precision
Medtronic reports FDA approval of Simplera CGM; partners with Abbott
OncoBeta expands Rhenium-SCT (Skin Cancer Therapy) treatment services in Italy
Labcorp's PGDx elio plasma focus Dx receives US FDA De Novo marketing authorisation
Verici Dx announces completion of Thermo Fisher Scientific licensing agreement
Polarean Imaging enters into trade-in agreement with University of Kansas Medical Center